NetraMark Holdings Inc. announces that it will present new data supporting the potential of its proprietary NetraAI clinical trial solution to de-risk clinical trials for neurology therapies by identifying the key variables that drive clinical trial success and providing testable hypotheses to guide clinical trial design. The data will be presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) 20th Annual Meeting, which is taking place February 21-23 in Washington, DC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.315 CAD | 0.00% | +1.61% | -10.00% |
1st Jan change | Capi. | |
---|---|---|
-10.00% | 15.45M | |
+8.05% | 3,020B | |
+5.58% | 82.93B | |
+3.69% | 76.85B | |
-14.62% | 53.04B | |
+31.16% | 50.15B | |
-24.56% | 46.55B | |
+17.75% | 41.41B | |
+55.21% | 35.63B | |
-10.24% | 24.64B |
- Stock Market
- Equities
- AIAI Stock
- News NetraMark Holdings Inc.
- NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials